3SBio Revenue and Competitors

Shanghai ,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • 3SBio's estimated annual revenue is currently $71.6M per year.(i)
  • 3SBio's estimated revenue per employee is $155,000

Employee Data

  • 3SBio has 462 Employees.(i)
  • 3SBio grew their employee count by -8% last year.

3SBio's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is 3SBio?

关于三生制药集团 三生制药集团是一家集研发、生产和销售为一体的生物制药领军企业,致力于以高品质的药品提高患者生存质量,为人类健康造福。目前,集团拥有80余项国家发明专利授权,30余种上市产品,覆盖肿瘤、自身免疫、肾病、代谢及皮肤科等治疗领域。集团拥有抗体药物国家工程研究中心以及生物药和化药双平台的4大研发中心,共有25种在研产品,其中16种作为国家一类新药正在研发,并拥有符合GMP标准的6大生产基地。未来,三生制药集团将继续秉持“珍爱生命、关注生存、创造生活”的理念,全力打造全球领先的中国生物制药企业。 About 3S Pharmaceutical Group 3S Pharmaceutical Group is a leading bio-pharmaceutical company integrating R&D, production and sales, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Group owns more than 80 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Group owns 4 R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 25 kinds of products under R&D, 16 kinds of them are under R&D as the national first-class new drugs. The Group also owns 6 production bases complying with GMP standards. In the future, 3S Pharmaceutical Group will continue to uphold the concept of “Care for Life, Cherish Life, Create Life” to create a world's leading bio-pharmaceutical company in China.

keywords:N/A

N/A

Total Funding

462

Number of Employees

$71.6M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

3SBio News

2022-04-19 - rhEPO Market Overview, High Growth Opportunities ...

rhEPO Market Overview, High Growth Opportunities, Segmentation, Trends By 2022-2028 | 3SBio, Biosidus, NCPC Genetech, Shanghai Chemo, Ahua...

2022-04-19 - Recombinant Human Erythropoietin Rhepo Market Size 2022 ...

3sbio; Shanghai Chemo; Chengdu Diao; Ncpc Genetech; Kyowa Hakko Kirin; Shandong Kexing; Ahua Pharmaceutical; Biosidus; Dragon Pharma.

2022-03-30 - 3SBio : announces 2021 annual results, with net profit attributable to owns of the parents almost doubling under accelerated growth of diversified businesses

3SBio continued to be rated A in MSCI ESG Ratings in 2021, surpassing 78% of the world's biotech companies. The Company has been named in the...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$117.8M469N/AN/A
#2
$79.4M512-2%N/A
#3
$131.5M5131%N/A
#4
$183.6M5340%N/A
#5
$9570M6995%N/A